obesity - identifying and commercializing first-in-class innovation

www.MarketResearchReports.com

Frontier Pharma: Obesity - Identifying and Commercializing

First-in-Class Innovation

Category : Pharma & Healthcare

All logos and Images mentioned on this slide belong to their respective owners.


Introduction to Report

Launch Date: October 1, 2015

Number of Pages: 87

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 6,995

Price For Site User License: USD 13,990

Price For Global User License: USD 20,985

Delivery Time: Within 24 Hours (During Working Days)


About the Report

Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation report provides analysis of the obesity treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the obesity therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared.


Key Highlights:

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients.

However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect.

Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.


Key Highlights Continues… The company’s latest report states that despite the

current market’s clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class.

Senior Analyst, says that while most pipeline products target gut hormone receptors, the remainder target a wide range of processes thought to be dysregulated in obesity, such as angiogenesis, insulin signaling, inflammation, fat absorption, lipid synthesis, and metabolism.

The high level of innovation and diversity in molecular target in development is encouraging, with a number of these not only showing close alignment to the disease pathophysiology but also addressing multiple mechanisms underpinning the development of obesity.


Reasons to Buy:

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the available treatment options and their limitations in terms of safety and efficacy.

Visualize the composition of the obesity market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities.

Analyze the obesity pipeline and stratify by stage of development, molecule type, and molecular target; the diversity of molecular targets in the pipeline is extremely encouraging as obesity is characterized by the complex interplay between central and peripheral mechanisms.


Reasons to Buy Continues… Assess the therapeutic potential of first-in-class targets

using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential.

Target the most promising and innovative obesity products for early-stage investment by analyzing trends in licensing and co-development deals and accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.


Report Coverage:

1. Executive Summary

2. The Case for Innovation

3. Clinical and Commercial Landscape

4. Assessment of Pipeline Product Innovation

5. Signaling Pathways, Genetics and Innovation Alignment

6. First-in-Class Target Evaluation

7. Deals and Strategic Consolidations

8. Appendix

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.


Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

http://www.marketresearchreports.com/idea-center

http://www.marketresearchreports.com/subscribe-to-newsletter

http://www.marketresearchreports.com/subscribe-to-newsletter


How To Buy This Report?Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/oXY

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)

http://mrr.cm/oXY

http://mrr.cm/oXY

mailto:[email protected]